Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations

American Journal of Clinical Pathology

Volumn 127, Issue 4, 2007, Pages 580-584

  Tigrani, Dean Yar ^a   Weydert, Jamie A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b 5239C RCP ^*  (United States)

Author keywords

Immunohistochemistry; Mesothelioma; Osteopontin

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUTOPSY; BIOPSY; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIOID CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; OSTEOPONTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 34247130951     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/BME4VG11LDX8KMTN     Document Type: Article

References (26)

1. Churg A, Cagle FT, Roggli VL. Tumors of the Serosal Membranes. Silver Spring, MD: ARP Press; 2006. Atlas of Tumor Pathology; Fourth Series, Fascicle 3.
2. Travis WD, Brambilla E, Muller-Hermelink HK, et al, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours.
3. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19:514-523.
4. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005;129:1421-1427.
5. Reinholt FP, Hultenby K, Oldberg A, et al. Osteopontin: a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990;87:4473-4475.
6. Baccarini-Contri M, Taparelli F, Pasquali-Ronchetti I. Osteopontin is a constitutive component of normal elastic fibers in human skin and aorta. Matrix Biol. 1994;14:553-560.
7. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509-512.
8. Darling MR, Gauthier M, Jackson-Boeters L, et al. Osteopontin expression in salivary gland tumours. Oral Oncol. 2006;42:363-369.
9. Tuck AB, Hota C, Wilson SM, et al. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene. 2003;22:1198-1205.
10. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002;62:3417-3427.
11. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med. 1997;121:578-584.
12. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001;6:419-429.
13. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 1999;5:2271-2277.
14. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184-190.
15. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79:502-508.
16. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancer. Lung Cancer. 1996;15:311-323.
17. Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett. 2001;171:215-222.
18. Donati V, Boldrini L, Dell'Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 2005;11:6459-6465.
19. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513-521.
20. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287:1671-1679.
21. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79:127-132.
22. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353:1564-1573.
23. Cullen MR. Serum osteopontin levels: is it time to screen asbestos-exposed workers for pleural mesothelioma [editorial]? N Engl J Med. 2005;353:1617-1618.
24. Eskelinen MJ, Haglund UH. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eur J Surg. 1999;165:292-306.
25. Bloomer JR, Waldmann TA, McIntire KR, et al. Alpha-fetoprotein in nonneoplastic hepatic disorders. JAMA. 1975;233:38-41.
26. Sabattini E, Bisgaard K, Ascani S, et al. The EnVision+ + system: a new immunohistochemical method for diagnostics and research: critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol. 1998;51:506-511.